The American Psychopathological Association (APPA), founded in 1910, is devoted to the scientific investigation of disordered human behavior and its biological and psychosocial substrates. Its primary function is to sponsor an annual conference on a specific topic relevant to research in psychopathology. Leading investigators from the U.S. and abroad are invited to give original papers on the topic chosen by the President.

This annual conference provides a unique opportunity to learn about, discuss, and debate cutting edge issues in the topic area. It is open to all mental health professionals and trainees, as well as APPA members.

Annual Meeting

The annual conference is held in Manhattan beginning the first Thursday of March and ending on the following Saturday at noon. The next meeting, Substance Use, Substance Use Disorders: Changing Concepts, Changing Patterns, will take place March 5-7, 2020 at the Crowne Plaza Times Square in New York. Please check our Registration page for more information and for the downloadable form. Attendees may register early for a significant discount.

Participants at the annual conference include students, mental health scientists and practitioners. Therefore another important APPA function is to provide a forum for high level professional and social contact between established investigators, younger researchers, interested clinicians, and trainees. Special registration rates are available for students attending the meeting.

2020 Meeting Program



For over a century, APPA has brought diverse groups of researchers, policy makers and scholars together to an annual meeting where vital issues and developments in psychopathology are presented and discussed. Although the meeting is open to all mental health professionals and researchers, the bulk of those attending belong to the community of APPA members. The members are active basic and clinical researchers whose observations, questions and insights are always valuable. Indeed, a unique feature of the APPA annual meetings is that there is a single series of presentations on a specific theme and there is scheduled discussion that involves members of the audience.

More About APPA Membership

Psychedelics: Risks and Opportunity - APPA Fall 2019 Webinar - November 20, 2019, 12:00-1:00pm EST

Please join us for a preview of the APPA March, 2020 conference on “Substance Use, Substance Use Disorders” via web conference featuring a presentation and discussion on the risks and therapeutic opportunities for psychedelics with Deborah Hasin, Professor of Epidemiology (in Psychiatry) at Columbia University, and Matthew Johnson, Director of the Psychedelic Center at Johns Hopkins Department of Psychiatry and Behavioral Sciences. Psychedelics, such as psilocybin, mescaline, and LSD, are a class of drugs capable of inducing mental, visual, and auditory hallucinations, altered sense of time and consciousness, and include possible adverse reactions such as nausea and panic. In the mid 20th century, psychedelics showed promise for the treatment of two conditions: end-of-life psychiatric distress and addiction. Despite initial enthusiasm within psychiatry for the therapeutic potential of psychedelics, public concern about nonmedical use led to increasingly restrictive laws and eventual status as a Schedule I controlled substance. Recent studies in Europe and the US have once again sparked interest into the therapeutic potential of psychedelics, particularly psilocybin, for conditions such as mood and anxiety disorders, and addiction.

(Note that registration for the webinar requires creating a username and password for After you register, you will receive an email with instructions on how to join the online conference by computer or phone.)

2019 Webinar Registration - Open to All